IOL Chemicals Secures NMPA Approval in China for Clopidogrel Bisulfate API
IOL Chemicals & Pharmaceuticals Ltd has received significant regulatory approval for its Active Pharmaceutical Ingredient (API), 'Clopidogrel Bisulfate,' from Chinese authorities. The Centre for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA), China, granted the approval on 14th July 2026.This critical regulatory milestone expands IOL Chemicals' reach into the highly regulated Chinese pharmaceutical market. The NMPA approval complements an existing Certificate of Suitability (CEP) that the company holds for Clopidogrel Bisulfate.The successful attainment of this approval further strengthens the company's overall regulatory...